A Phase II Open-Label Study of Subcutaneous CPG ODN (PF03512676) in Combination With Trastuzumab in Patients With Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2016
At a glance
- Drugs Agatolimod (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 13 Jan 2016 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Jun 2013 Planned end date changed from 1 Jan 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.